• Title

  • Michelle Wu Appointed to RI Bio Board

    RI Bio, Southeastern New England’s life sciences trade group, announced the appointment of Michelle Wu of Wu Consulting to its board of directors at its July 20 meeting. Ms. Wu is a medical device leader specializing in strategic planning, product management, and operational improvement for the med tech industries. Her company focuses on helping start-ups bring their medical technology innovations to life by bringing clarity, alignment and calm to the chaotic and unknown.   
     
    “We are honored to have Michelle join our board and bring us the benefit of her two decades of experience in the life sciences,” said Carol Malysz, RI Bio Executive Director. “She has been an invaluable member of our Life Sciences Advisory Board, and I look forward to her leadership on the board. 
     
    “I am excited and grateful to be joining the board at RI Bio,” said Ms. Wu. “I look forward to contributing and working through RI Bio to strengthen the RI area life sciences ecosystem.” 
     
    Ms. Wu has a history of successful medical device product development, strategic planning and execution, building teams, process evolution, and managing organizational change.  She values a collaborative and diverse, equitable, and inclusive environment, believing that diverse perspectives lead to the best ideas, more cohesive teams, and better results. Previously, she has served on the executive leadership team of Ximedica (now Veranex), a design and development medical technology consultancy in Rhode Island.  
     
    About RI Bio 
    As the trade group and voice of southeastern New England’s life sciences industry, RI Bio fosters strategic partnerships that can create a healthier world and grow the life sciences economy. They serve as a catalyst for biotech industry acceleration, advocating for better policy, educating a strong life science workforce, collaborating with life sciences companies, hospitals, universities, capital sources and government agencies, sharing information and expertise, and promoting the advancement of science. The result is improved quality of life, advanced innovation and discovery, and a robust life sciences ecosystem. 

/* AZU-560-12875 */ /* AZU-560-12875 */